- Home
- VOR vs TOI Comparison
VOR vs TOI Comparison
Compare VOR & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOR | TOI |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.1M | 327.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VOR | TOI |
|---|---|---|
| Price | $12.06 | $2.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $64.78 | $6.00 |
| AVG Volume (30 Days) | 956.5K | ★ 2.1M |
| Earning Date | 03-19-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $461,039,000.00 |
| Revenue This Year | N/A | $28.51 |
| Revenue Next Year | N/A | $25.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.67 |
| 52 Week Low | $2.62 | $0.60 |
| 52 Week High | $65.80 | $4.88 |
Technical Indicators
Market Signals| Indicator | VOR | TOI |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 27.50 |
| Support Level | $13.00 | $3.30 |
| Resistance Level | $15.00 | $3.23 |
| Average True Range (ATR) | 1.41 | 0.22 |
| MACD | -0.45 | -0.09 |
| Stochastic Oscillator | 8.68 | 1.99 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.